COMMUNIQUÉS West-GlobeNewswire

Alimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmology

08/11/2017 - 13:30

ATLANTA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that data from [...]

Tyme Provides Clinical and Corporate Update for the Fiscal First Half 2017

08/11/2017 - 13:30

NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq: TYME ), a clinical-stage biotechnology company developing cancer therapeutics, today announced an update of its clinical and corporate [...]

Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer

08/11/2017 - 13:30

GERMANTOWN, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR ), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the appointment of David Recker, [...]

TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results

08/11/2017 - 13:30

NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX ) today announced its financial results for the third quarter ended September 30, 2017, and recent company developments. Michael S. Weiss, [...]

Immunovaccine Announces Regulatory Clearance for Phase 2 Clinical Trial Evaluating DPX-Survivac in Combination with Merck’s Checkpoint Inhibitor Pembrolizumab in DLBCL

08/11/2017 - 13:05

HALIFAX, Nova Scotia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage vaccine and immuno-oncology company, today announced that Health Canada has granted Sunnybrook [...]

AroCell AB: Abstract published presenting AroCell TK 210 ELISA from the PROMIX study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017

08/11/2017 - 09:31

AroCell AB (publ) announces today that the abstract entitled: "Quantification of cell loss in breast cancer during neoadjuvant treatment (NACT) assessed by serum thymidine kinase protein concentrations (sTK1)", by B [...]

Lundbeck increased operating profit (EBIT) with 126% and EPS by 182% in the first nine months of 2017

08/11/2017 - 07:45

Valby, Denmark, 2017-11-08 07:45 CET (GLOBE NEWSWIRE) -- HIGHLIGHTS Revenue reached DKK 12,842 million in the first nine months of 2017 representing an increase of 12% (13% in local currencies) compared to the same [...]

ThromboGenics Strengthens Leadership Team - Susan Schneider, MD appointed Chief Medical Officer and Vinciane Vangeersdaele appointed Chief Commercial Officer

08/11/2017 - 07:30

Press release Leuven, Belgium - 8 November 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today [...]

Photocure ASA: Results for the third quarter of 2017

08/11/2017 - 07:17

Oslo, Norway, 7 November 2017: Photocure ASA (OSE: PHO ), today reported a revenue growth of 45% for the important US market in the third quarter of 2017, contributing to Hexvix/Cysview revenues of NOK 35.5 million (Q3 [...]

Voyager Therapeutics Announces Pricing of Public Offering of Common Stock

08/11/2017 - 04:55

CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR ), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, [...]

VALNEVA Signs $39.6 Million IXIARO® Supply Contract with US Government

08/11/2017 - 02:06

Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, announces today the signing of a $39.6 million one year contract with [...]

Sun BioPharma Announces Execution of Reverse Stock Split

08/11/2017 - 01:21

MINNEAPOLIS, Minn., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, announced [...]

Corizon Health Partners with Missouri Department of Corrections to Serve Incarcerated Veterans

07/11/2017 - 23:49

BRENTWOOD, Tenn., Nov. 07, 2017 (GLOBE NEWSWIRE) -- US military veterans account for an estimated 181,500 inmates in US prisons and jails, according to the most recent numbers available from the federal Bureau of [...]

Almost Family Reports Third Quarter and Year to Date 2017 Results

07/11/2017 - 23:21

LOUISVILLE, Ky., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Almost Family, Inc. (NASDAQ: AFAM ), a leading national provider of home health and related services, announced today its financial results for the quarter ended [...]

National Research Corporation Announces Third Quarter 2017 Results

07/11/2017 - 23:00

LINCOLN, Neb., Nov. 07, 2017 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ: NRCIA ) (NASDAQ: NRCIB ) today announced results for the third quarter of 2017. Net New Sales $5.4 million Total Contract Value $ [...]

Amedisys Reports Third Quarter 2017 Financial Results

07/11/2017 - 23:00

BATON ROUGE, La., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED ) today reported its financial results for the three and nine-month periods ended September 30, 2017. Three Month Periods Ended September [...]

Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

07/11/2017 - 22:57

BURNABY, British Columbia, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE ), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September [...]

Profound Medical Corp. Announces Third Quarter 2017 Financial Results

07/11/2017 - 22:45

TORONTO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V: PRN ) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time [...]

ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights

07/11/2017 - 22:40

-- Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 -- -- Patient enrollment ongoing in registration-supporting trial for avacopan in the treatment C3 Glomerulopathy (C3G) -- -- [...]